| Item type |
学術雑誌論文 / Journal Article(1) |
| タイトル |
|
|
タイトル |
Early Experience of Liver Resection Following Atezolizumab and Bevacizumab Therapy for Hepatocellular Carcinoma with Vascular Invasion |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Hepatocellura carcinoma |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
immuno-checkpoint inhibitor |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
vascular invasion |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 著者 |
Takada, Musashi
Tajima, Hidehiro
Kawasaki, Keishi
Tatsuoka, Teppei
Meguro, Souya
Ishido, Hirotaka
Okuyama, Takashi
Kusano, Yumi
Tamano, Masaya
Ban, Shinichi
Yoshitomi, Hideyuki
|
| 書誌情報 |
en : Dokkyo Medical Journal
巻 3,
号 3,
p. 178-187,
発行日 2024-09-25
|
| 記事種別 |
|
|
|
Original |
| 内容記述 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
The effectiveness of surgical resection for hepatocellular carcinoma (HCC) with vascular invasion (VI) remains controversial, and the multidisciplinary treatment combining chemotherapy and surgical resection may improve the prognosis of these patients. Recently, atezolizumab and bevacizumab (AB) therapy has shown favorable survival benefits and tumor responses for HCC. In this study, we analyzed HCC patients with VI treated with liver resection following AB therapy to evaluate the safety and efficacy of this multidisciplinary treatment.
A retrospective analysis was performed of 76 HCC patients who received AB therapy as initial treatment at Dokkyo Medical University Saitama Medical Center between 2020 and 2023. Seventeen patients with VI were divided into two groups: receiving hepatectomy (ABH group) and not (AB group).
The response rate was significantly higher in the ABH group (ABH: 71.4% vs. AB: 10%, p = 0.035). There was no difference in adverse events between the two groups. In the ABH group, the median operative time was 398 (229-533) minutes, and the median blood loss was 315 (130-590) ml. There were no complications of Clavien-Dindo ≥IIIa. R0 resection was achieved in six patients, and pathological complete remission was seen in three. One patient had hepatic recurrence at ten months postoperatively, but the others survived without recurrence.
The surgical resection following AB therapy can be performed safely for HCC with VI. In addition, the pathological examination showed favorable results for this treatment. A prospective study should be conducted to confirm the safety and efficacy of this treatment. |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
Dokkyo Medical Society |
| ISSN |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
2436-522X |
| 書誌レコードID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA12941861 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 他の資源との関係 |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.51040/dkmj.2023-053 |
DKMJ-3-3-2.pdf (159 KB)
.png)
